Showing results (1271-1280 of 1,368) with videos related to

Sort By:
Pageof 137
Frontiers in Cell and Developmental Biology|September 26, 2024
Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapyMengying Xia, Mahboubeh Varmazyad, Iris Pla-Palacín, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 14, 2022
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessmentDaniela A Bota, Thomas H Taylor, David E Piccioni, et al.
Respiratory Medicine|June 5, 2025
Health-related quality of life after 12 Months of discharge from specialized weaning centers for post-COVID-19 patients: A multicenter cohort studyEmiliano Navarro, Darío Villalba, Amelia Matesa, et al.
British Journal of Haematology|January 24, 2014
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patientsAlberto Rocci, Manuela Gambella, Simona Aschero, et al.
Cell|April 3, 2018
Fetal Neuropathology in Zika Virus-Infected Pregnant Female Rhesus MonkeysAmanda J Martinot, Peter Abbink, Onur Afacan, et al.
Leukemia|September 22, 2012
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patientsP Falco, F Cavallo, A Larocca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trialAntonio Palumbo, Sara Bringhen, Davide Rossi, et al.
Nature Communications|March 25, 2026
First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trialAngela Damato, Riziero Esposito Abate, Simona Tessitore, et al.
Blood|March 19, 2021
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myelomaAlessandra Larocca, Francesca Bonello, Gianluca Gaidano, et al.
Lancet (London, England)|July 10, 2002
Association between conformational mutations in neuroserpin and onset and severity of dementiaRichard L Davis, Antony E Shrimpton, Robin W Carrell, et al.
Pageof 137